15th May 2007 07:04
Dechra Pharmaceuticals PLC15 May 2007 Issued on behalf of Dechra Pharmaceuticals PLCDate: Tuesday, 15 May 2007 Embargoed:7.00am Dechra Pharmaceuticals PLC ("Dechra" or "the Group") Dechra Strengthens its US Veterinary Product Portfolio Dechra today announces that it has secured a long-term trademark license andsupply agreement with Pharmaderm Animal Health ("Pharmaderm"), part of the UScommercial division of ALTANA Inc. The agreement provides the Group with exclusive marketing and distributionrights for a range of veterinary licensed ophthalmic, otic and dermatologicalproducts and the opportunity to develop new veterinary licenses for both NorthAmerica and Europe. Under the agreement, Dechra will pay US$5million in cash for the licenses. Theproducts, which are currently sold to veterinary practices in the USA, achievedsales of US$7.7 million in the year ended 31 December 2006. This range of specialist products, which will continue to be manufactured byALTANA's US commercial division on behalf of Dechra, will be marketed anddistributed under the Dechra Veterinary Products brand livery. The agreementwill provide the opportunity for the Group to increase sales and to strengthenits profile and brand awareness within the American veterinary market ahead ofthe launch of its own developed veterinary products, Vetoryl(R), Felimazole(R)and Equidone(R) which are currently undergoing FDA review. Ian Page, Chief Executive, Dechra Pharmaceuticals PLC said: "We are delighted to have significantly strengthened our range of specialistveterinary medicines for the US market. We are confident that our technical andmarketing expertise can increase market penetration of this specialist productrange and, when combined with our own-developed products, will enable us toestablish a much stronger foothold and brand awareness within the US-veterinarycompanion animal market, the largest in the world." Enquiries:Ian Page, Chief Executive Fiona Tooley, DirectorSimon Evans, Group Finance Director Citigate Dewe RogersonDechra Pharmaceuticals PLC Telephone: +44 (0) 121 455 8370Telephone: +44 (0) 1782 771100 Mobile: +44 (0) 7785 703523Mobile: +44 (0) 77756 42222 (IP)Mobile: +44 (0) 7775 642220 (SE)www.dechra.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
DPH.L